Related Experiment Videos
Alemtuzumab in T-cell malignancies
Claire E Dearden1, Estella Matutes, Daniel Catovsky
1St. George's Hospital Medical School, London, UK. claire.dearden@stgeorges.nhs.uk
Medical Oncology (Northwood, London, England)
|August 16, 2002
Summary
Alemtuzumab effectively treats aggressive T-cell malignancies like T-cell prolymphocytic leukemia and cutaneous T-cell lymphoma, offering hope for patients with poor prognoses.
Area of Science:
- Oncology
- Immunology
- Hematology
Background:
- Alemtuzumab targets the CD52 antigen on T-lymphocytes.
- T-cell malignancies are aggressive and often have poor prognoses.
Purpose of the Study:
- To evaluate alemtuzumab's efficacy in treating various T-cell malignancies.
- To assess treatment tolerability and complications.
Main Methods:
- Alemtuzumab administered at 30 mg thrice weekly.
- Patients with T-cell prolymphocytic leukemia (T-PLL), cutaneous T-cell lymphoma (CTCL), T-cell large granular lymphocyte (T-LGL) leukemia, and adult T-cell leukemia-lymphoma (ATLL) were treated.
Main Results:
- Overall response rates of 76% in T-PLL (60% complete response) and 100% in CTCL.
- Common first-dose reactions; main complication was infection due to prolonged lymphopenia.
- Limited data for T-LGL and ATLL require further investigation.
Conclusions:
- Alemtuzumab demonstrates significant activity in T-cell malignancies, especially T-PLL.
- Potential for prolonged response with high-dose therapy and stem cell transplantation.
- Alemtuzumab may aid in minimal residual disease purging.